Atherosclerotic Cardiovascular Disease
📧 Sign up to get email alerts when something new happens for Atherosclerotic Cardiovascular Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2026-08-17FDA Approved: ROSUVASTATIN CALCIUM — Supplemental Application (Glenmark Pharmaceutials Inc., USA)
FDA supplemental approval for a rosuvastatin calcium product from Glenmark Pharmaceuticals Inc. USA.
-
FDA approval · 2026-08-17FDA Approved: ROSUVASTATIN — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA supplemental application approval for Camber Pharmaceuticals' rosuvastatin product.
-
FDA approval · 2026-08-05FDA Approved: SIMVASTATIN — Supplemental Application (WATSON LABS TEVA)
A supplemental application approval for simvastatin by Watson Labs Teva, indicating a formulation/label change under an ANDA submission.
-
FDA approval · 2026-08-04FDA Approved: FENOFIBRATE — Supplemental Application (Bostal LLC)
Supplemental approval for fenofibrate from Bostal LLC.
-
FDA label_change · 2026-07-31FDA Approved: ROSUVASTATIN CALCIUM — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA supplemental approval for rosuvastatin calcium from Torrent Pharmaceuticals Limited.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2026-07-31FDA Approved: ROSUVASTATIN CALCIUM — Supplemental Application (Rising Pharma Holdings, Inc.)
Supplemental approval for rosuvastatin calcium by Rising Pharma Holdings, Inc..
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease [Phase 3]
Phase III trial evaluating HRS9531 for atherosclerotic cardiovascular disease is listed as not yet recruiting.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity [Phase 3]
This document notes a Phase 3 clinical trial (NCT07037433) evaluating Maridebart Cafraglutide for cardiovascular outcomes in adults with ath…
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia [Phase 2]
Phase 2 study of olezarsen (formerly AKCEA-APOCIII-LRx) in adults with hypertriglyceridemia and atherosclerotic cardiovascular disease or se…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD [NA]
Clinical trial update describing a study of a moderate-intensity statin plus ezetimibe in patients with chronic kidney disease and atheroscl…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab
This real-world clinical trial update reports on long-term adherence and persistence to inclisiran, evolocumab, and alirocumab among patient…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Health Enhanced Artery Risk Tracking With Widespread Implementation and Screening Effort in ASCVD (HEARTWISE-ASCVD) [NA]
This document describes the HEARTWISE-ASCVD clinical trial, a study evaluating health-enhanced artery risk tracking with wide implementation…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Notification of Incidental Coronary Artery Calcium in Patients With Atherosclerotic Cardiovascular Disease (NOTIFY-ASCVD) [NA]
The NOTIFY-ASCVD clinical trial, studying incidental coronary artery calcium in patients with atherosclerotic cardiovascular disease, has co…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Oral Microbiome in Carotid Atherosclerosis
A recruiting clinical trial is examining how the oral microbiome relates to carotid atherosclerosis, including atherosclerotic cardiovascula…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Aspirin 50 mg vs. 100 mg in Elderly Cardiovascular Disease Patients
The document reports a clinical trial comparing low-dose (50 mg) versus higher-dose (100 mg) aspirin in elderly patients with atheroscleroti…
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) [Phase 3]
Phase 3 study evaluating Muvalaplin for reducing major cardiovascular events in adults with elevated lipoprotein(a) and ASCVD. The trial is …
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Development and Multicenter Validation of an AI-Based Remote Photoplethysmography (rPPG) Facial Scan for Multimodal Health Assessment
This trial update covers the development and multicenter validation of an AI-based remote photoplethysmography (rPPG) facial scan for multim…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) [Phase 3]
A Phase 3 clinical trial update assessing Lepodisiran for reducing major adverse cardiovascular events in adults with elevated lipoprotein(a…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) [Phase 3]
A Phase 3 trial update for retatrutide in obesity assessing cardiovascular and kidney outcomes (TRIUMPH-Outcomes) is currently active but no…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event [Phase 3]
A Phase III study of AZD0780 to evaluate major adverse cardiovascular events in patients with a history of ASCVD or at high risk for a first…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) [Phase 3]
A Phase 3 clinical trial (ATTAIN-Outcomes) evaluating Orforglipron (LY3502970) for cardiovascular outcomes in adults with atherosclerotic ca…
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD [Phase 3]
Phase 3 clinical trial update evaluating Lp(a) lowering with pelacarsen (TQJ230) plus background inclisiran in participants with elevated Lp…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Adherence to Dyslipidemia Therapy: Harnessing Evidence From Randomized Evaluations in AtheroSclerotic CardioVascular Disease [NA]
An update on a randomized evaluation study investigating adherence to dyslipidemia therapy in patients with atherosclerotic cardiovascular d…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Pelacarsen Roll-over Extension Program [Phase 3]
This clinical trial update indicates a roll-over extension program for pelacarsen in Phase 3 for atherosclerotic cardiovascular disease is c…
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease [Phase 3]
Phase 3 clinical trial update for inclisiran to prevent cardiovascular events in people with established atherosclerotic cardiovascular dise…